VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
XERS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
XERSXeris Biopharma Holdings, Inc.
$16.99$2.9B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksXERSBalance Sheet

Xeris Biopharma Holdings, Inc. (XERS) Balance Sheet

10Y historyFree accessUpdated daily

Total debt surged to $289.4M in 2026Q2 from $37.8M in 2025Q4, driving equity to -$9.7M and a current ratio of 1.45, indicating heightened leverage and thinner liquidity.

Income StatementBalance SheetCash FlowRatios

XERS Balance Sheet

Annual statement

XERS Balance Sheet

Xeris Biopharma Holdings, Inc. (XERS) balance sheet — 10-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16
Total Current Assets289.26M240.31M167.66M156.26M186.82M142.6M152.21M87.48M117.9M44.05M33.17M
Cash & Short-Term Investments131.08M111.04M71.62M72.45M121.97M102.43M133.79M75.55M112.63M42.05M32.27M
Cash Only131.08M111.04M71.62M67.45M121.97M67.27M37.6M19.52M45.72M42.05M32.27M
Short-Term Investments0005M035.16M96.19M56.03M66.92M00
Accounts Receivable68.6M51.05M40.41M39.2M30.83M17.46M6.88M4.69M2.87M1.2M101K
Days Sales Outstanding57.9963.8572.6487.28102.07128.48122.8629.3424.82281.2634.29
Inventory76.92M68.67M48.17M38.84M24.73M18.12M8.35M2.18M000
Days Inventory Outstanding478.93469.29477.41494.88398.88496.55326.85495.47---
Other Current Assets12.66M9.55M7.45M5.78M9.29M000000
Total Non-Current Assets133.95M143.21M155.4M166.34M157.7M161.76M6.94M21.5M2.13M945K359K
Property, Plant & Equipment26.22M27.06M28.21M29.18M9.51M6.63M6.71M7.85M2.03M788K312K
Fixed Asset Turnover13.78x10.79x7.20x5.62x11.60x7.48x3.05x0.35x1.21x1.97x3.45x
Goodwill22.86M22.86M22.86M22.86M22.86M22.86M00000
Intangible Assets79.95M88.08M98.92M109.76M120.61M131.45M00000
Long-Term Investments4.02M04.12M000013.23M000
Other Non-Current Assets4.93M5.22M-4.81M4.54M4.73M829K232K420K95K157K47K
Total Assets423.22M383.53M323.06M322.6M344.52M304.36M159.15M108.99M120.03M45M33.53M
Asset Turnover0.91x0.76x0.63x0.51x0.32x0.16x0.13x0.02x0.02x0.03x0.03x
Asset Growth %80.38%18.72%0.14%-6.36%13.2%91.24%46.03%-9.2%166.74%34.19%-
Total Current Liabilities134.48M109.57M100.44M95.19M73.62M79.04M28.21M27.34M10.17M4.86M2.53M
Accounts Payable8.04M3.08M2.29M11.56M4.61M8.92M3.12M5.6M866K1.98M1.31M
Days Payables Outstanding50.8321.0222.69147.3674.28244.58121.971.28K7.53K180.31K60K
Short-Term Debt06.23M15.1M00000000
Deferred Revenue (Current)00000000232K234K263K
Other Current Liabilities4.02M100.27M39.75M51.43M27.23M25.63M11.2M9.06M4.98M1.3M468K
Current Ratio2.15x2.19x1.67x1.64x2.54x1.80x5.40x3.20x11.59x9.06x13.13x
Quick Ratio1.58x1.57x1.19x1.23x2.20x1.57x5.10x3.12x11.59x9.06x13.13x
Cash Conversion Cycle486.09512.11527.36434.8426.67380.46327.68-151.02---
Total Non-Current Liabilities239.96M260.26M252.23M234.19M225.71M130.09M97.18M67.21M34.45M97.97M62.94M
Long-Term Debt189.71M31.53M217.01M190.93M187.07M88.07M87.02M58.3M31.89M00
Capital Lease Obligations60.55M033.26M34.76M9.4M000000
Deferred Tax Liabilities0002.27M3.52M4.94M00000
Other Non-Current Liabilities20.24M228.73M1.97M6.23M25.72M37.08M10.16M8.91M2.56M97.97M62.94M
Total Liabilities374.44M369.84M352.68M329.38M299.33M209.13M125.39M94.55M44.62M102.83M65.47M
Total Debt226.07M37.76M271.45M229.19M198.06M88.07M87.02M58.3M31.89M00
Net Debt94.98M-73.28M199.83M161.74M76.09M20.8M49.42M38.79M-13.83M-42.05M-32.27M
Debt / Equity4.63x2.76x--4.38x0.92x2.58x4.04x0.42x--
Debt / EBITDA3.81x1.02x---------
Net Debt / EBITDA1.60x-1.98x---------
Interest Coverage0.50x0.02x-0.80x-1.39x-5.81x-16.09x-10.95x-16.60x-22.61x-13277.00x-6603.50x
Total Equity48.78M13.69M-29.61M-6.78M45.19M95.23M33.76M14.44M75.41M-57.83M-31.93M
Equity Growth %6098.81%146.22%-336.67%-115.01%-52.55%182.07%133.87%-80.86%230.39%-81.09%-
Book Value per Share0.260.08-0.20-0.050.331.210.790.556.26-28.51-17.33
Total Shareholders' Equity48.78M13.69M-29.61M-6.78M45.19M95.23M33.76M14.44M75.41M-57.83M-31.93M
Common Stock19K17K15K14K14K13K6K3K2K1K1K
Retained Earnings-688.88M-671.31M-671.86M-617.02M-554.77M-460.11M-337.38M-246.25M-120.67M-60.59M-34.03M
Treasury Stock00000000000
Accumulated OCI-11K-25K-25K-25K-23K-31K6K43K-52K-440K-268K
Minority Interest00000000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityStable
Balance SheetMixed
Cash FlowImproving
Top Statement Risk

Debt refinancing and negative equity

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Balance Sheet Strengthens Amid Debt Shift

Total assets grew 24% year-over-year to $411.9M in 2026Q2, while total debt surged from $37.8M to $289.4M, per the latest quarterly filing, indicating a strategic shift toward leverage.

The balance sheet has expanded significantly, driven by a major debt increase in 2026Q2, likely from a convertible note issuance. This has boosted cash reserves to $121.7M, but also introduced substantial leverage. The trajectory suggests a deliberate move to fund growth, though it raises the stakes for execution.

Leverage Spikes with New Debt

Total debt jumped from $37.8M in 2025Q4 to $289.4M in 2026Q2, pushing D/E from 2.76 to negative equity, as reported in financial statements, signaling a major refinancing event.

The debt increase appears strategic, likely to fund operations and provide a cash buffer, but it has pushed equity negative. With negative equity, the D/E ratio is not meaningful, but the absolute debt level is high relative to assets. Investors should monitor the terms and maturity of this debt, as refinancing risk could emerge if cash flows falter.

Asset Mix Reflects Asset-Light Model

PP&E remains modest at $26.6M, just 6.5% of total assets, while goodwill is stable at $22.9M, per the latest balance sheet, indicating a low fixed-asset base and limited impairment risk.

The asset base is dominated by cash and intangibles, consistent with a biotech model. Goodwill has remained constant, suggesting no impairments, but the lack of tangible assets means the balance sheet is sensitive to cash burn. The minimal PP&E underscores the asset-light nature, which supports the positive FCF trend seen in cash flow statements.

Negative Equity Worsens Despite Profits

Equity fell to -$9.7M in 2026Q2 from $13.7M in 2025Q4, as accumulated deficits reached -$700.2M, per SEC filings, despite recent operating profits, highlighting persistent losses.

The negative equity is driven by massive retained earnings deficits, which have grown despite operational improvements. The $31.1M net loss in 2026Q2, including high SBC, has eroded equity further. This suggests that while the company is approaching breakeven, it remains dependent on external financing to sustain its balance sheet.

Liquidity Bolstered by Cash Infusion

Cash rose to $121.7M in 2026Q2 from $111.0M in 2025Q4, while the current ratio fell to 1.45 from 2.19, as per the latest balance sheet, indicating a thinner short-term buffer.

The cash position is strong, but the current ratio decline suggests that current liabilities have grown faster than current assets, likely due to the new debt. With operating cash flow turning positive, the company appears to have adequate liquidity for near-term needs, but the debt load increases the risk of a cash crunch if revenue growth stalls.

Debt Refinancing Risk Looms

The $289.4M debt, up from $37.8M in 2025Q4, may carry covenants or near-term maturities that could strain liquidity, as reported in the latest balance sheet, warranting close monitoring.

The sudden debt increase is the most non-obvious risk. While it provides cash, it also introduces refinancing risk and potential interest expense that could pressure margins. The negative equity amplifies this risk, as the company may have limited access to additional credit. Investors should scrutinize the debt terms and the company's ability to service it from operating cash flows.

XERS — Frequently Asked Questions

Quick answers to the most common questions about buying XERS stock.

What are the total assets of Xeris Biopharma Holdings, Inc. (XERS)?

As of 2025, Xeris Biopharma Holdings, Inc. (XERS) had total assets of $383.5M including $240.3M in current assets.

How much debt does Xeris Biopharma Holdings, Inc. (XERS) have?

Xeris Biopharma Holdings, Inc. (XERS) carries total debt of $37.8M, offset by $111.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Xeris Biopharma Holdings, Inc.?

Xeris Biopharma Holdings, Inc. (XERS) has total shareholders' equity (book value) of $13.7M ($0.08 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Xeris Biopharma Holdings, Inc.'s current ratio and liquidity?

Xeris Biopharma Holdings, Inc. (XERS) reported a current ratio of 2.19x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.